To mitigate this issue, Ou et al. (2024) introduced an AAV-based gene therapy approach called RM-101 containing SmOPT snRNA and have showed high efficiency of skipping exon 13 in USH2A. Moreover, humanised mice treated with RM-101 have sustained USH2AΔex13 transcript expression and did not show any retinal abnormalities, offering a different perspective to treat USH2A-associated RP. Here, USH2A is linked to retinitis pigmentosa 1.